CMV drug, ATA230, granted orphan drug designation

Atara Biotherapeutics, Inc. announced that ATA230 was granted orphan drug designation for the treatment of cytomegalovirus (CMV) viremia and disease in immunocompromised patients by the U.S. Food and Drug Administration (FDA). ATA230, an allogeneic T-cell immunotherapy targeting antigens expressed by CMV, has been investigated in one Phase 1 and two Phase 2 clinical studies in ["]

The post CMV drug, ATA230, granted orphan drug designation appeared first on Outbreak News Today.